Compare WM & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WM | GSK |
|---|---|---|
| Founded | 1968 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8B | 116.3B |
| IPO Year | 2002 | N/A |
| Metric | WM | GSK |
|---|---|---|
| Price | $224.19 | $57.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $256.37 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 3.9M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 1.68% | ★ 3.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.70 | N/A |
| Revenue | ★ $14,485,000,000.00 | N/A |
| Revenue This Year | $8.25 | $6.70 |
| Revenue Next Year | $5.45 | $4.22 |
| P/E Ratio | $33.57 | ★ $32.75 |
| Revenue Growth | ★ 6.44 | N/A |
| 52 Week Low | $194.11 | $35.45 |
| 52 Week High | $248.13 | $61.70 |
| Indicator | WM | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 59.04 |
| Support Level | $220.46 | $47.89 |
| Resistance Level | $231.11 | $60.37 |
| Average True Range (ATR) | 4.29 | 1.04 |
| MACD | -0.46 | 0.45 |
| Stochastic Oscillator | 8.95 | 70.76 |
WM, previously known as Waste Management, ranks as the largest integrated provider of traditional solid waste services in the United States, operating 257 active landfill sites and about 342 transfer stations that help with transporting waste efficiently and economically. The company serves residential, commercial, industrial, and medical end markets for waste collection, transfer, and disposal. The company also has an energy business emanating from the beneficial use of landfill gas and is a leading recycler in North America.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.